Page results
-
Our team deliver care to people with MS and aim to provide specialist services, share information on how to manage symptoms, offer education sessions, medication options and rehabilitation services.
-
The Neurometabolic unit provides a unique range of investigations and clinical laboratory advice encompassing mitochondrial, neurotransmitter, pterin and amino acid disorders.
-
The clinical management of neuromuscular muscle wasting diseases such as motor neuron disease, myasthenia gravis, muscular dystrophy and peripheral neuropathy.
-
Typically, patient care is multidisciplinary led by consultant neuro-ophthalmologists and neurologists.
-
The department is responsible for a wide range of neurophysiological procedures, principally electromyography (EMG) and nerve conduction studies, EMG-guided botulinum toxin (BoTox) injections, electroencephalography (EEG), evoked potentials (EPs) and intra-operative monitoring (IOM)
-
The plasma exchange service at the National Hospital treats patients with neuroimmunological diseases such as Guillain-Barré syndrome and myasthenia gravis.
-
We provide a specialist spinal surgery service including treatment of degenerative spinal conditions, artificial discs, spinal injury, spinal tumours (intra and extra dural, including metastatic disease), scoliosis and syringomyelia.
-
AutoLab is a dual haematology and biochemistry laboratory which operates as a public private partnership between Sonic Healthcare pty (The Doctors Laboratory) and UCLH NHS Foundation Trust Hospitals Laboratories.
-
Autoimmune serology is provided for: Connective tissue diseases, Endocrine diseases, Liver diseases, Rheumatic diseases, Skin diseases, Thyroid diseases.
-
The department has a special interest in sexually transmitted viral infections and viral infections in relation to hepatitis, bone marrow transplants and HIV-related viral resistance.
File results
-
FOI/2024/0401 - Hospital treatments for abortion complications
-
FOI/2024/0402 - Various IT systems used at the Trust
-
FOI/2024/0403 - Risk Policy and corporate risk register
-
FOI/2024/0406 - Staff and patient discrimination complaints in 2021, 2022 and 2023
-
FOI/2024/0416 - Home dialysis treatment
-
FOI/2024/0420 - Commercialisation of NHS patient data
-
FOI/2024/0417 - Funding for point-of-care home blood monitoring devices for cancer patients
-
FOI/2024/0512 - Patient harm and the cost 2020-2023
-
FOI/2024/0415 - Biologic and targeted medications within dermatology medicine
-
FOI/2024/0412 - Healthcare travel costs scheme for patients